Swissmedic only issues WHO Certificates in Accordance with the new Format
![Drug Master File Procedures in the EU, the US and Japan - Live Online Training](files/eca/userImages/training.img/Z-ECA-Drug-Master-File-Procedures-LOT.jpg)
Recommendation
17/18 September 2024
With updates on the CEP 2.0!
A CPP (Certificate of a Pharmaceutical Product) certifies the marketability of a medicinal product in the country of origin. The certificates are issued by the authority of the country where the medicinal product is manufactured and authorised (exporting country). These can then serve competent authorities of importing third countries in the following regulatory situations:
- In the context of applications for marketing authorisation
- In the context of applications for renewal, extension, variation or review of a marketing authorisation.
The WHO (World Health Organisation) recommends the use of a standardised format for this certificate.
From 20 March 2023, Swissmedic will issue CPPs in the new WHO format (according to TRS 1033 - 55th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations; Annex 9). The changes are detailed in the new version of guidance document BW302_00_001e.
No CPP orders can be accepted during the transition (13 to 19 March 2023) to the new format. Orders for CPPs in the old format can be submitted via the portal until 12 March 2023. From 20 March 2023, new orders can only be submitted using the new input file. The new version of guidance document BW302_00_001e and the new input file will be available on the Swissmedic website from 13 March 2023.
Source: Swissmedic
Related GMP News
26.06.202410 points on how the FDA's CDER monitors the Quality of Medicinal Products
08.05.2024EMA Plans for the next three Years
30.04.2024Lean GMP: is "right-sizing" GMP and Compliance possible?
24.04.2024Unexpected Deviations: the Role of the QP
10.04.2024FDA's current Thinking on KPIs and Quality Metrics
21.02.2024What is the African Medicines Agency?